Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?

To: lwd who wrote (528)	9/22/1999 1:35:00 PM
From: Susan Saline	Respond to of 569

it reads like doctors write ... illegible gg some fundamental and teechnicals for BXM techstocks.com

To: lwd who wrote (528)	9/22/1999 1:50:00 PM
From: Orlando Stevenson	Respond to of 569

Gee, these folks need some marketing spin doctors like those from MS to help them out .. the following bottomline comment sure isn't a standout theme in the overall release. "This data will demonstrate the value of Synvisc and will be important to patients and healthcare providers."

To: lwd who wrote (528)	9/22/1999 10:17:00 PM
From: James Baker	Read Replies (1) \| Respond to of 569

It read like this one. I put NAIC into Yahoo and got back Native American Intertribal Councils as the first hit. But I do like this stock and I am gld to see the recent tremendous relative strength [what ever the reason!] Biomatrix to Exhibit at NAIC National Congress & Expo NAIC NATIONAL CONGRESS & EXPO, NASHVILLE, Tenn., Sept. 15 /PRNewswire/ -- Biomatrix, Inc. is the worldwide leader in the development and manufacture of viscoelastic products made from proprietary biological polymers called hylans that are used in therapeutic medical applications and in skin care products. The company's lead product, Synvisc®, is a novel, non-drug therapeutic used to provide long-term pain relief for those who suffer from osteoarthritic knee pain. Synvisc is marketed by Wyeth-Ayerst Laboratories in the US and certain European and Middle Eastern countries; Boehringer-Ingelheim in France; Rhone-Poulenc Rorer in Canada; F. Hoffmann-La Roche Ltd. in Sweden and South Africa; Novartis Pharma AG throughout Latin America; and Bayer AG in Australia, New Zealand and certain countries in Asia. Biomatrix developed and manufactures several other viscoelastic medical therapeutics. Hylaform® is an injectable viscoelastic hylan gel treatment for the correction of facial wrinkles and depressed scars. It is marketed in 23 countries by Collagen Aesthetics, Inc. (now Inamed Corp.) (OTC Bulletin Board: IMDC - news). Gelvisc® Vet is an elastoviscous hylan product for the treatment of arthritis in veterinary medicine that is distributed by Boehringer-Ingelheim in France and Equinord in Sweden. Biomatrix' Hylashield® products are viscoelastic therapeutics for the protection of the surface of the eye from noxious environmental conditions and are distributed in Canada by I-MED Pharma, Inc. The company also manufactures nine patented elastoviscous intermediates for the skin care industry. Biomatrix has recorded three consecutive years of profitability, and ten consecutive quarters of profitability. As of June 30, 1999, the company had approximately $22 million in cash and $63.4 million in shareholders' equity. Biomatrix' strategy to build several core assets on the strength of its lead product, Synvisc, has proven successful. Moving forward, the company's next goal will be to continue to advance its pipeline of future products toward commercialization and continue to build on its leadership position in the development and commercialization of viscoelastic medical therapeutics. SOURCE: Biomatrix, Inc.

To: lwd who wrote (528)	9/23/1999 9:26:00 AM
From: SC	Read Replies (1) \| Respond to of 569

As I read it, the CEO said they are waiting for official release of the data but obviously he wanted it to be known as a good news. He probably has his reasons for not giving more details before the independent researchers do for their own work. He said: "We look forward to the release of full trial results from this landmark study in the peer reviewed literature. This data will demonstrate the value of Synvisc and will be important to patients and healthcare providers." This recently completed trial was designed, managed and reported by an independent academic steering committee of international opinion leaders in compliance with published guidelines for pharmacoeconomic studies. Fourteen clinical investigators, specialists in both rheumatology and orthopedics, conducted the study over the past two years with patients from all across Canada.